Recently, Lim and colleagues[32] have also demonstrated that NGAL involved in the progression of epithelial ovarian malignanciesmay and may be served as an early screening biomarker to monitor changes of benign to premalignant and malignant ovarian tumors. Here, LCN2 is linked to ovarian cancer.